EpimAb Biotherapeutics has successfully implemented the NewCo model through two significant deals in 2024-2025: licensing EMB-06 to Vignette Bio and a T-cell engaging molecule to Juri Biosciences.
This article explores the intersection of virology and oncology, examining how scientists harness viruses' natural abilities to combat cancer. Unibest is pleased to present an oncolytic virus asset, currently in Phase II trials, that is open for global licensing and co-development opportunities.
Obesity is a global health crisis affecting over 650 million people worldwide. But there's hope on the horizon. Recent breakthroughs in understanding how our gut and pancreatic hormones regulate appetite and blood sugar have led to the development of exciting new medicines to treat obesity and relat
The Kv1.3 channel, a classical Shaker-type potassium channel, holds a unique place in cellular biology. Unibest presents two Kv1.3 inhibitor assets, UB024 and UB029, for NewCo and License opportunities.
In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.
The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.